Showing results (31-40 of 187) with videos related to
Sort By:
Pageof 19
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2019
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaGilles Salles, Ajay K Gopal, Monique C Minnema, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2008
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest doseJoseph G Rajendran, Ajay K Gopal, Darrel R Fisher, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.Clinical Lymphoma, Myeloma & Leukemia|February 8, 2017
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) ChemotherapyAbby E Floeter, Amila Patel, Melinda Tran, et al.Blood Advances|January 4, 2018
Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantationAng Li, Chris Davis, Qian Wu, et al.Experimental Hematology|January 25, 2017
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implicationsElahe A Mostaghel, Paul S Martin, Stephen Mongovin, et al.Blood|May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.British Journal of Haematology|January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaLihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.Anti-Cancer Drugs|August 4, 2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulationAndrew J Cowan, Shani L Frayo, Oliver W Press, et al.Nuclear Medicine Communications|September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testesNaoya Hattori, Ajay K Gopal, Andrew T Shields, et al.Pageof 19